Research across Psoriasis
Related studies from across the Psoriasis family.
Guselkumab, Secukinumab, and Brodalumab rank highly for PASI 75 and PASI 90 in plaque psoriasis
New data ranks different treatments for moderate to severe psoriasis
This systematic review and network meta-analysis of 27 RCTs evaluated IL-23/IL-17 inhibitors for moderate-to-severe plaque psoriasis. Guselk…
Comparing several types of biologics helps patients with plaque psoriasis find which medications rank highest for clearing skin and improvin…
Obesity is associated with lower PASI90, PASI75, and PASI100 responses in patients with psoriasis
Obesity May Impact How Well Certain Psoriasis Drugs Work
This meta-analysis of 4200 patients found that obesity is associated with lower PASI90 (RR = 0.64), PASI75 (RR = 0.52), and PASI100 (RR = 0.…
New data suggests that patients with obesity may see lower response rates to certain biologic treatments for psoriasis.
Calcium signaling dysregulation drives keratinocyte defects and immune activation in psoriasis
Calcium signaling problems may drive the cycle of psoriasis
This systematic review synthesizes evidence that impaired calcium sensing and SOCE dysfunction in keratinocytes, alongside persistently acti…
New research identifies how faulty calcium signals in skin cells and immune cells could be a key driver of psoriasis symptoms.
Combination therapies of plant-derived compounds outperform monotherapy for psoriasis vulgaris with specific immunological profiles
Plant compounds combined with standard care improve psoriasis symptoms
This systematic review and network meta-analysis of 84 randomized controlled trials involving 7,544 patients found that combination therapie…
Combining specific plant-derived ingredients with standard treatments may offer better results for people living with psoriasis.
SSGJ-608 achieves 92.7% to 95.1% PASI75 response in moderate-to-severe plaque psoriasis
New injection shows promise for moderate to severe plaque psoriasis
This phase 3 randomized trial in 770 patients with moderate-to-severe plaque psoriasis found that SSGJ-608 (80mg every 2 weeks or 160mg ever…
A new injectable treatment showed high success rates in clearing skin and improving appearance for people with plaque psoriasis.
Staphylococcal infections may mimic paradoxical psoriasis in patients receiving TNF-alpha inhibitors for systemic conditions
Skin infections can mimic psoriasis during certain medical treatments
This case report series describes 6 patients treated with TNF-alpha antagonists who developed skin lesions initially misdiagnosed as paradox…
Some patients treated for skin conditions may actually have a bacterial infection that looks like a flare-up of their original condition.
Smoking and alcohol linked to higher psoriasis risk in large meta-analysis
Smoking raises psoriasis risk significantly while alcohol shows a smaller effect
This systematic review and meta-analysis of observational studies involving more than 25 million participants found that smoking (RR 1.67) a…
Smoking increases the chance of developing psoriasis, and even quitting keeps that risk higher than never smoking. Alcohol also plays a role…
High-certainty evidence suggests weight-loss interventions improve psoriasis severity and quality of life in adults
Weight loss linked to better psoriasis severity and quality of life
This systematic review and meta-analysis evaluated weight-loss interventions versus usual care or lower-intensity interventions in adults wi…
A review of 1,145 adults with psoriasis found weight-loss interventions improved skin severity and quality of life more than usual care.
Icotrokinra 200 mg daily achieves PASI 75 in 73% of patients at Week 16 versus 11% with placebo in moderate-to-severe plaque psoriasis
Oral icotrokinra shows strong results for moderate-to-severe plaque psoriasis
This systematic review and meta-analysis evaluates icotrokinra for moderate-to-severe plaque psoriasis in 1951 patients. The pooled analysis…
A new analysis finds oral icotrokinra helps clear skin faster than placebo in patients with moderate-to-severe plaque psoriasis.
Switching between adalimumab and biosimilar adalimumab-atto shows similar pharmacokinetics in plaque psoriasis
Switching between adalimumab and its biosimilar is safe and similar
This phase 3 RCT in 425 adults with moderate-to-severe plaque psoriasis found that multiple switches between adalimumab RP and biosimilar ad…
A new trial shows that switching between adalimumab and its biosimilar adalimumab-atto is safe and produces similar drug levels in the blood…
Narrative review offers theoretical basis for selecting biologic therapies in psoriasis patients with renal concerns
New Psoriasis Treatments May Protect Kidneys While Fighting Skin Flares
This narrative review examines the use of TNF-alpha, IL-17, and IL-12/23 inhibitors in psoriasis patients with renal concerns. The authors p…
• Some biologics shield kidneys from damage during psoriasis treatment • Helps the 8 million Americans with psoriasis and kidney worries • N…
Targeted therapies for psoriasis and psoriatic arthritis significantly alter lipid profiles across diverse patient populations
Psoriasis drugs change heart risk in surprising ways
A comprehensive meta-analysis of 24,575 patients reveals that targeted therapies for psoriasis and psoriatic arthritis consistently modify l…
Some common psoriasis drugs sharply raise cholesterol while others lower it, forcing doctors to rethink how they protect their patients’ hea…